Genprex announced that its gene therapy candidate REQORSA, designed to deliver the tumor suppressor gene TUSC2, induces cellular repair and maintenance pathways in lung cancer patients, potentially enhancing resilience to aging-related stress. The findings from blood analyses in clinical trials revealed a shift from an initial immune response to increased mitochondrial adaptation, autophagy, and protein quality control after treatment. This research expands understanding of REQORSA's therapeutic benefits beyond oncology, suggesting a role for TUSC2 in aging processes. Genprex plans to further explore these effects as it advances its clinical programs for lung cancer and diabetes.
Genprex's gene therapy candidate REQORSA is the subject, with this Pluang market snapshot for health-sector US stocks as of Nov 05, 2026 19:01 WIB: Out of 150 stocks, 94 rose and 48 fell. Among notable movers, LFST gained 3.24% to USD 14.67 with a typical hold time of 13 days, while CI and MEDP both rose 3.14%, priced at USD 315.00 and USD 677.36 respectively; CI had a notably longer typical hold time of 67 days and 100% buy order activity on Pluang.
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
